Subspecialty Anatomic Pathology
Reliable, high-quality anatomic pathology at Inform Diagnostics starts with our premier team of GU pathologists—all subspecialists. It continues with our wide range of reflex testing options and our investment in modernized systems for seamless and sustainable urologic pathology services.
Our premier urologic pathologists
Many of our urologic pathologists are current or former professors at some of the world’s leading institutions.
Our urologic pathologists are always available to directly answer your questions and leverage their collective expertise (including daily case review conferences) to ensure patients receive the most accurate results.
Comprehensive areas of disease focus in urology
At InformDx, our systematic subspecialization is a foundational aspect of our collaborative approach to pathology. This subspecialty expertise, along with experience gained from seeing more cases than the average urologic pathologist, is leveraged during consensus case conferences that help to ensure patients receive the right diagnosis, the first time.
Our urologic pathologists’ subspecialty expertise includes:
- Detection and screening (including biomarkers of diagnosis)
- Early cancer (including active surveillance, biomarkers of outcome, and grading)
- Advanced cancer (including targets and outcomes)
- Detection (including urine cytology and biomarkers of diagnosis/UroVysion)
- Early cancer (including dysplasia, CIS, superficial tumors, biomarkers of outcome, and staging)
- Advanced cancer (including staging, variant histology, and targets)
- Testicular and paratesticular tumors
- Premalignant and malignant
Definitive diagnoses for urology patients
Our team of urologic pathologists utilize advanced, in-house testing to provide academic-caliber, definitive diagnoses. Our workflow incorporates reflex send-out testing options including Prolaris® and other testing options for clinicians who request it.
Actionable detail from prostate cancer grading
We provide highly detailed pathology reports to provide maximum clinical value. Learn more about prostate biopsy reports from InformDx.
Know their cancer risk with the PINgenius™ Test
Developed by our pathology laboratory services team at InformDx, the PINgenius™ Test allows patients with HG-PIN diagnoses to prepare for the future by predicting the risk of invasive prostate cancer at re-biopsy.
EHR and workflow optimization
We use interface capabilities to help your practice workflow:
- Send pathology orders and receive results through EHR interface technology
- Additional clinical photos and detail sent to aid in pathology diagnoses
- Bidirectional interface capabilities improve the communication between clinicians and Inform Diagnostics pathologists
“[Inform Diagnostics] has made our life much easier by providing the necessary technology, the most professional service and excellent customer service. We are very happy and grateful about our business relationship.”
Office Manager, Urologist
Case studies for urology
We have highlighted patient cases where the subspecialty expertise and collaborative diagnostic approach at InformDx has made a difference—including consultation to identify a rare condition, and further testing to avoid unnecessary surgery for the patient.
Forms & Requisitions
Submit specimens to our uropathology lab
View and download forms for current clients to submit specimens to our uropathology lab and learn how first-time clients can get in touch with our team at InformDx.
Recent publications in urology
Inform Diagnostics fosters an academic environment where ongoing research and education are encouraged. We are proud of the peer-reviewed research our uropathologists have published, including pioneering work in areas such as atypical intraductal proliferation, intraductal carcinoma of prostate (IDC-P), PTEN and ERG expression in prostate cancer.
Assessment of prospectively assigned Likert scores for targeted MR imaging-transrectal US fusion biopsies in patients with suspected prostate cancer
Published in Journal of Urology, 2016. Authors: Costa D, Lotan Y, Rofsky NM, Roehrborn C, Liu A, Hornberger B, Xi Y,[...]
An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-preliminary experience
Published in Urologic Oncology, April 2017. Authors: Costa DN, Kay FU, Pedrosa I, Kolski L, Lotan Y, Roehrborn CG, Hornberger B,[...]
Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy
Published in Urologic Oncology, January 2019. Authors: Freifeld Y, Xi Y, Passoni N, Woldu S, Hornberger B, Goldberg K, Bagrodia A,[...]